DNA Bioscience Hires Global Healthcare Expert to New Role of CEO
Advertisement
London. DNA Bioscience, a leading DNA testing company, today announced that it has appointed John Rowley to the new role of CEO. Rowley, whose past experience includes working for International SOS, Diageo and GlaxoSmithKline in a variety of senior international management positions, will take up his post on 20th July 2005.
DNA Bioscience was founded in 2003 and has already established a leading reputation in the expanding DNA testing market, with services including testing for paternity and ethnicity, forensics and DNA preservation. It is one of the few DNA companies to be certified by the Department for Constitutional Affairs and to have ISO accreditation.
Rowley commented on his appointment:
"I see huge growth potential within the DNA testing industry, not only in the UK but also in Europe, Asia and North America. Building on DNA Bioscience's existing reputation for high service levels and innovation and the strength of the existing management team, I know that we can rapidly develop the company and make DNA Bioscience the most recognised name within its industry."
John McKinley, chairman of DNA Bioscience adds:
"We are delighted to attract the calibre of John Rowley to DNA Bioscience. His international experience in building brands, managing fast growing companies and establishing key corporate partnerships will provide very important attributes to our current management team. In a short time, we have already established a recognised leading position in the market and with John's leadership we will achieve our ambitious goals for the company."
Immediately prior to joining DNA Bioscience, John Rowley was Regional Managing Director, EMEA, for International SOS, the world's leading healthcare and medical assistance company, where his responsibilities included managing the European and Middle East region with revenues in excess of US$60million and overseeing 240 staff. He began his career working for the pharmaceutical division of GlaxoSmithKline in London, rapidly progressing from management trainee to Area Manager, Middle East, within five years. He then worked for over 10 years with Diageo Plc, in various general management and sales and marketing positions in the UK and then Asia, covering both large, established markets and smaller scale emerging markets.
Other news from the department people
These products might interest you
Most read news
More news from our other portals
Last viewed contents
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases
The Linde Group and Algenol Biofuels agree to cooperate in CO2 and O2 management for biofuel production from algae
RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.
Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics
Biomass for biofuels, biochemicals will more than triple to 3.7 billion tons in 2030
Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology
U.S. Department Of Defense selects Applied Biosystems for development of instrument system to identify infectious diseases
NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD
